Canada - English - Health Canada

fresenius kabi canada ltd - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors

Canada - English - Health Canada

teva canada limited - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors

Canada - English - Health Canada

teva canada limited - eptifibatide - solution - 0.75mg - eptifibatide 0.75mg - platelet aggregation inhibitors

Canada - English - Health Canada

omega laboratories limited - eptifibatide - solution - 0.75mg - eptifibatide 0.75mg - platelet aggregation inhibitors

Canada - English - Health Canada

omega laboratories limited - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors

Canada - English - Health Canada

strides pharma canada inc - eptifibatide - solution - 0.75mg - eptifibatide 0.75mg - platelet aggregation inhibitors

Canada - English - Health Canada

strides pharma canada inc - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors

Canada - English - Health Canada

accord healthcare inc - eptifibatide - solution - 0.75mg - eptifibatide 0.75mg - platelet aggregation inhibitors

Canada - English - Health Canada

accord healthcare inc - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - eptifibatide 0.75 mg/ml (75 mg in 100 ml) - solution for infusion - 0.75 mg/ml - active: eptifibatide 0.75 mg/ml (75 mg in 100 ml) excipient: citric acid monohydrate sodium hydroxide water for injection - indicated for patients undergoing non-urgent, percutaneous coronary intervention (pci) with coronary stenting for the reduction of death, myocardial infarction, urgent revascularisation and the need for acute antithrombotic rescue therapy. indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction. indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide is intended for use with aspirin, heparin or clopidigrel.